Evidence map›Paper›PMID 37522187›Full record

ArticleJournal of psychopharmacology (Oxford, England)2023

Improving Translational Relevance in Preclinical Psychopharmacology (iTRIPP).

Sarah J Bailey, Tobias Bast, Lauren Chaby, Bruce J Kinon, Michael K Harte, Sally Mead, Rachel D Moloney, Ian Ragan, S Clare Stanford, Mark D Tricklebank and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of psychopharmacology (Oxford, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 3 countries.

Sarah J BaileyDepartment of Life Sciences, University of Bath, Bath, UK.ORCID 0000-0003-4492-8479
Tobias BastSchool of Psychology and Neuroscience@Nottingham, University of Nottingham, Nottingham, UK.
Lauren ChabyModerna, Cambridge, MA, USA.
Bruce J KinonKaruna Therapeutics, Boston, MA, USA.
Michael K HarteDivision of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Sally MeadIndependent Lived Experience Consultant, Manchester, UK.
Rachel D MoloneySchool of Pharmacy, Department of Pharmacology and Therapeutics, APC Microbiome Ireland, University College Cork, Cork, Ireland.
Ian RaganIndependent Consultant for the National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs).
S Clare StanfordDepartment of Neuroscience, Physiology and Pharmacology University College London, London, UK.ORCID 0000-0002-5623-1751
Mark D TricklebankCentre for Neuroimaging Sciences, Institute of Psychiatry Psychology and Neuroscience, King's College London, London, UK.
Mark ZervasCohen Veterans Bioscience, New York, NY, USA.
Laura A AjramMedicines Discovery Catapult, Macclesfield, UK.ORCID 0000-0001-5745-5805
Cohen Veterans Bioscience · USCyclerion (United States) · USManchester Academic Health Science Centre · GBMedicines Discovery Catapult · GBNational Centre for the Replacement Refinement and Reduction of Animals in Research · GBUniversity College Cork · IEUniversity College London · GBUniversity of Bath · GBUniversity of Nottingham · GBWellcome Centre for Human Neuroimaging · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Animal models are important in preclinical psychopharmacology to study mechanisms and potential treatments for psychiatric disorders. A working group of 14 volunteers, comprising an international team of researchers from academia and industry, convened in 2021 to discuss how to improve the translational relevance and interpretation of findings from animal models that are used in preclinical psychopharmacology. The following paper distils the outcomes of the working group's discussions into 10 key considerations for the planning and reporting of behavioural studies in animal models relevant to psychiatric disorders. These form the iTRIPP guidelines (Improving Translational Relevance In Preclinical Psychopharmacology). These guidelines reflect the key considerations that the group thinks will likely have substantial impact in terms of improving the translational relevance of behavioural studies in animal models that are used to study psychiatric disorders and their treatment. They are relevant to the research community when drafting and reviewing manuscripts, presentations and grant applications. The iTRIPP guidelines are intended to complement general recommendations for planning and reporting animal studies that have been published elsewhere, by enabling researchers to fully consider the most appropriate animal model for the research purpose and to interpret their findings appropriately. This in turn will increase the clinical benefit of such research and is therefore important not only for the scientific community but also for patients and the lay public.

Indexed as

Mental DisordersPsychopharmacologyAnimalsDisease Models, AnimalHumansanimal modelspreclinical researchpsychiatric disordersPsychopharmacologytranslation

Identifiers

PMID37522187
PMCPMC10647891
OpenAlexW4385406126

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.